• 37
  • 8
  • 收藏

Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults

Dow Jones2021-11-26

MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults

Merck $(MRK)$ and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. "Nine deaths were reported in the placebo group, and one in the molnupiravir group," the companies said in a joint statement. "The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis." The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论8

  • Jeffchew
    ·2021-11-26
    Ok
    回复
    举报
  • Walt3089
    ·2021-11-26
    这结果。。。
    回复
    举报
  • JhNerdy
    ·2021-11-26
    Like comment follow 
    回复
    举报
  • weng1245
    ·2021-11-26
    Give a like
    回复
    举报
  • LiverpoolNBA
    ·2021-11-26
    Oh my..
    回复
    举报
  • Anniechen169
    ·2021-11-26
    ok
    回复
    举报
    收起
  • thecham
    ·2021-11-26
    Ok
    回复
    举报
    收起
    • SallyNeo
      Ok
      2021-11-26
      回复
      举报
  • Syww
    ·2021-11-26
    [Strong] [Strong] 
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24